BACKGROUND: The purpose of this study was to determine the incidence of hypothyroidism after chemoradiation in head and neck squamous cell cancer (HNSCC). METHODS: One hundred twenty-two patients treated with 3-dimensional conformal radiotherapy (3DCRT; 70 Gy/35#) or intensity-modulated radiation therapy (IMRT; 66 Gy/30#) in 2 identical simultaneous randomized trials were studied. Thyroid function was assessed at baseline and every 3 to 6 monthly thereafter. Development of subclinical (thyroid-stimulating hormone [TSH] >4.67 μIU/mL) or biochemical (T4 <4.5 μg/dL) hypothyroidism was noted. Multivariate analyses were done to determine the factors associated with hypothyroidism. RESULTS: At a median of 41 months, 55.1% of the patients developed hypothyroidism (39.3% subclinical, 15.7% biochemical). The IMRT arm had higher subclinical hypothyroidism (51.1% vs 27.3%; p = .021) peaking around 1 year postradiotherapy in both arms. Younger age, hypopharynx/larynx primary, node positivity, higher dose/fraction (IMRT arm), and D100 were statistically significant factors for developing hypothyroidism. CONCLUSION: Postradiotherapy hypothyroidism peaks at 1 year. Higher dose per fraction possibly led to greater incidence of hypothyroidism in the IMRT cohort.
BACKGROUND: The purpose of this study was to determine the incidence of hypothyroidism after chemoradiation in head and neck squamous cell cancer (HNSCC). METHODS: One hundred twenty-two patients treated with 3-dimensional conformal radiotherapy (3DCRT; 70 Gy/35#) or intensity-modulated radiation therapy (IMRT; 66 Gy/30#) in 2 identical simultaneous randomized trials were studied. Thyroid function was assessed at baseline and every 3 to 6 monthly thereafter. Development of subclinical (thyroid-stimulating hormone [TSH] >4.67 μIU/mL) or biochemical (T4 <4.5 μg/dL) hypothyroidism was noted. Multivariate analyses were done to determine the factors associated with hypothyroidism. RESULTS: At a median of 41 months, 55.1% of the patients developed hypothyroidism (39.3% subclinical, 15.7% biochemical). The IMRT arm had higher subclinical hypothyroidism (51.1% vs 27.3%; p = .021) peaking around 1 year postradiotherapy in both arms. Younger age, hypopharynx/larynx primary, node positivity, higher dose/fraction (IMRT arm), and D100 were statistically significant factors for developing hypothyroidism. CONCLUSION: Postradiotherapy hypothyroidism peaks at 1 year. Higher dose per fraction possibly led to greater incidence of hypothyroidism in the IMRT cohort.
Authors: Chelsea C Pinnix; Laura Cella; Therese Y Andraos; Zeina Ayoub; Sarah A Milgrom; Jillian Gunther; Sonali Thosani; Christine Wogan; Manuel Conson; Vittoria D'Avino; Yasuhiro Oki; Michelle Fanale; Hun J Lee; Sattva Neelapu; Luis Fayad; Frederick Hagemeister; M Alma Rodriguez; Loretta J Nastoupil; Yago Nieto; Wei Qiao; Roberto Pacelli; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-14 Impact factor: 7.038
Authors: Graeme B Mulholland; Han Zhang; Nhu-Tram A Nguyen; Nicholas Tkacyzk; Hadi Seikaly; Daniel O'Connell; Vincent L Biron; Jeffrey R Harris Journal: J Otolaryngol Head Neck Surg Date: 2015-09-11
Authors: Ren Luo; Vincent W C Wu; Binghui He; Xiaoying Gao; Zhenxi Xu; Dandan Wang; Zhining Yang; Mei Li; Zhixiong Lin Journal: BMC Cancer Date: 2018-05-18 Impact factor: 4.430